British drug giant GSK is reportedly in talks to acquire cancer drugmaker Nuvalent. The deal could be worth over nine billion dollars. Discussions are ongoing, with an agreement potentially this week. This move comes amid a surge in biotech acquisitions as large companies seek to boost their drug pipelines. Nuvalent focuses on targeted cancer therapies.